JP2005535298A5 - - Google Patents

Download PDF

Info

Publication number
JP2005535298A5
JP2005535298A5 JP2004505087A JP2004505087A JP2005535298A5 JP 2005535298 A5 JP2005535298 A5 JP 2005535298A5 JP 2004505087 A JP2004505087 A JP 2004505087A JP 2004505087 A JP2004505087 A JP 2004505087A JP 2005535298 A5 JP2005535298 A5 JP 2005535298A5
Authority
JP
Japan
Prior art keywords
glucan
human
locus
antibodies
discloses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004505087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535298A (ja
JP5110767B2 (ja
Filing date
Publication date
Priority claimed from GBGB0211118.5A external-priority patent/GB0211118D0/en
Application filed filed Critical
Publication of JP2005535298A publication Critical patent/JP2005535298A/ja
Publication of JP2005535298A5 publication Critical patent/JP2005535298A5/ja
Application granted granted Critical
Publication of JP5110767B2 publication Critical patent/JP5110767B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004505087A 2002-05-15 2003-05-15 グルカンベースのワクチン Expired - Fee Related JP5110767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines
GB0211118.5 2002-05-15
PCT/IB2003/002460 WO2003097091A2 (en) 2002-05-15 2003-05-15 Glucan-based vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009294467A Division JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン

Publications (3)

Publication Number Publication Date
JP2005535298A JP2005535298A (ja) 2005-11-24
JP2005535298A5 true JP2005535298A5 (enExample) 2012-07-26
JP5110767B2 JP5110767B2 (ja) 2012-12-26

Family

ID=9936711

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004505087A Expired - Fee Related JP5110767B2 (ja) 2002-05-15 2003-05-15 グルカンベースのワクチン
JP2009294467A Pending JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン
JP2012166700A Expired - Fee Related JP5684758B2 (ja) 2002-05-15 2012-07-27 グルカンベースのワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009294467A Pending JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン
JP2012166700A Expired - Fee Related JP5684758B2 (ja) 2002-05-15 2012-07-27 グルカンベースのワクチン

Country Status (14)

Country Link
US (4) US20050208079A1 (enExample)
EP (2) EP1891970B1 (enExample)
JP (3) JP5110767B2 (enExample)
AT (2) ATE497781T1 (enExample)
AU (1) AU2003241104A1 (enExample)
CA (2) CA2485847C (enExample)
CY (1) CY1108234T1 (enExample)
DE (2) DE60320979D1 (enExample)
DK (1) DK1506009T3 (enExample)
ES (1) ES2306871T3 (enExample)
GB (1) GB0211118D0 (enExample)
PT (1) PT1506009E (enExample)
SI (1) SI1506009T1 (enExample)
WO (1) WO2003097091A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US8071552B2 (en) * 2004-04-05 2011-12-06 Universite Bordeaux 2 Peptides and peptidomimetics binding to CD23
GB0420466D0 (en) * 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
PL2878307T3 (pl) 2005-06-27 2020-01-31 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
WO2007084661A2 (en) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2007127668A2 (en) * 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
WO2009134891A2 (en) * 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
AU2013203785B2 (en) * 2006-11-06 2016-11-17 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
JP4687644B2 (ja) 2006-12-22 2011-05-25 富士ゼロックス株式会社 画像処理装置、画像読取装置及び画像形成装置
US9439954B2 (en) 2007-11-26 2016-09-13 Glaxosmithkline Biologicals Sa Conjugated beta-1,3-linked glucans
CA2706617A1 (en) 2007-11-26 2009-06-25 Novartis Ag Adjuvanted glucans
US20110236489A1 (en) 2008-09-18 2011-09-29 Novartis Ag Vaccine adjuvant combinations
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
JP2012520289A (ja) * 2009-03-10 2012-09-06 パルメッド テバ リミテッド 新規なコプリヌス・コマトゥスおよびトレメッラ・メセンテリカキノコ菌株、それらの生産物および抽出物、ならびにそれらを含む組成物
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EA201291091A1 (ru) * 2010-05-14 2013-05-30 Олтек, Инк. Компоненты клеточной стенки дрожжей и их обнаружение
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー spr0096抗原およびspr2021抗原を含むキャリア分子
HRP20161354T1 (hr) 2012-03-07 2016-12-02 Glaxosmithkline Biologicals Sa Argininske soli agonista tlr7
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Streptococcuspneumoniae抗原の増強された製剤
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US10092646B2 (en) * 2012-04-30 2018-10-09 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
US20160017062A1 (en) 2013-03-12 2016-01-21 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
CN105593238B (zh) 2013-07-11 2020-09-08 诺华股份有限公司 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
US9885726B2 (en) * 2013-12-05 2018-02-06 Biothera, Inc. β-glucan assay methods
ES2857557T3 (es) * 2015-01-26 2021-09-29 Kaleido Biosciences Inc Compuestos terapéuticos de glicano y métodos relacionados de los mismos
CN104771498A (zh) * 2015-03-13 2015-07-15 臧海阳 一种治疗热毒蕴结型痄腮的中药组合物
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
KR102795692B1 (ko) * 2018-01-19 2025-04-16 밀테니 비오텍 비.브이. & 씨오. 케이지 키메라 항원 수용체를 발현하는 조절 t 세포
US11701417B2 (en) * 2019-03-27 2023-07-18 West Virginia University Vaccine formulation to protect against pertussis
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
AU2023225283A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.
EP4486387A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate consisting of or comprising at least a ss-glucan or a mannan

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466289B (sv) * 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
JPS6383012A (ja) * 1986-09-26 1988-04-13 Nonogawa Shoji:Kk 化粧料
JPH05503952A (ja) * 1989-09-08 1993-06-24 アルファ ベータ テクノロジー,インコーポレイティッド 可溶性グルカン類の製造方法
EP0471954A3 (en) 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ATE280235T1 (de) * 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
CN1094288A (zh) * 1993-04-23 1994-11-02 福建省微生物研究所 利用红色诺卡氏菌制造细胞壁骨架粉末的方法
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
JPH09309842A (ja) * 1996-05-20 1997-12-02 Kureha Chem Ind Co Ltd 新規な生理活性物質、その製造方法及び医薬組成物
AU760669B2 (en) * 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4230635B2 (ja) 2000-02-29 2009-02-25 富士フイルム株式会社 デジタルカメラ

Similar Documents

Publication Publication Date Title
JP2005535298A5 (enExample)
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
JP2006526414A5 (enExample)
DE69942911D1 (de) Trägerprotein eines polyepitops
ATE149841T1 (de) Impfstoffe gegen krebs und infektionskrankheiten
ATE390933T1 (de) Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
EP1018344A3 (en) HLA-restricted hepatitis B virus CTL epitopes
NO20050894L (no) Vaksinesammensetninger inneholdende beta-l-6-antigenmatriser
EE200100292A (et) Peptiidligandidega kinnituvate mitmeste immunogeensete komponentidega HBV tuuma antigeensed osakesed
ATE419007T1 (de) Antigenraster welche il-5, il-13 oder eotaxin präsentieren, zur behandlung von allergischen, eosinophilen erkrankungen
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
DK0588578T3 (da) Immunogener
EP2385059A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
DK1135158T3 (da) Forbedrede vacciner baseret på kimære immunglobulin-E-peptider
WO2003017032A3 (en) Computer-based methods of designing molecules
EP0881910A4 (en) USE OF IMMUNOCONJUGATES TO ENHANCE THE EFFICACY OF MULTI-STEP VACCINES STIMULATING IMMUNE REACTIONS IN CASCADE
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
CN1056816A (zh) 改良的疫苗组合物
EP1425423A4 (en) TRANSCUTANEOUS IMMUNIZATION AGAINST PAPILLOMA VIRUSES WITH VIRUSUAL PAPILLOMA VIRUS PARTICLES
DE60143810D1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
ATE447968T1 (de) Impfung mit immunisolierten und einen immunomodulator produzierenden zellen
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
Sarode O RCID